174 related articles for article (PubMed ID: 34185411)
1. Folate receptor α increases chemotherapy resistance through stabilizing MDM2 in cooperation with PHB2 that is overcome by MORAb-202 in gastric cancer.
Sakai H; Kawakami H; Teramura T; Onodera Y; Somers E; Furuuchi K; Uenaka T; Kato R; Nakagawa K
Clin Transl Med; 2021 Jun; 11(6):e454. PubMed ID: 34185411
[TBL] [Abstract][Full Text] [Related]
2. MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity.
Cheng X; Li J; Tanaka K; Majumder U; Milinichik AZ; Verdi AC; Maddage CJ; Rybinski KA; Fernando S; Fernando D; Kuc M; Furuuchi K; Fang F; Uenaka T; Grasso L; Albone EF
Mol Cancer Ther; 2018 Dec; 17(12):2665-2675. PubMed ID: 30262588
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer.
Wen Y; Graybill WS; Previs RA; Hu W; Ivan C; Mangala LS; Zand B; Nick AM; Jennings NB; Dalton HJ; Sehgal V; Ram P; Lee JS; Vivas-Mejia PE; Coleman RL; Sood AK
Clin Cancer Res; 2015 Jan; 21(2):448-59. PubMed ID: 25416196
[TBL] [Abstract][Full Text] [Related]
4. Antibody-drug conjugate MORAb-202 exhibits long-lasting antitumor efficacy in TNBC PDx models.
Furuuchi K; Rybinski K; Fulmer J; Moriyama T; Drozdowski B; Soto A; Fernando S; Wilson K; Milinichik A; Dula ML; Tanaka K; Cheng X; Albone E; Uenaka T
Cancer Sci; 2021 Jun; 112(6):2467-2480. PubMed ID: 33756060
[TBL] [Abstract][Full Text] [Related]
5. A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer.
Ning G; Zhu Q; Kang W; Lee H; Maher L; Suh YS; Michaud M; Silva M; Kwon JY; Zhang C; Lee C
BMC Cancer; 2021 Aug; 21(1):923. PubMed ID: 34399705
[TBL] [Abstract][Full Text] [Related]
6. Bmi-1-induced miR-27a and miR-155 promote tumor metastasis and chemoresistance by targeting RKIP in gastric cancer.
Li Y; Tian Z; Tan Y; Lian G; Chen S; Chen S; Li J; Li X; Huang K; Chen Y
Mol Cancer; 2020 Jun; 19(1):109. PubMed ID: 32580736
[TBL] [Abstract][Full Text] [Related]
7. METTL3 promotes oxaliplatin resistance of gastric cancer CD133+ stem cells by promoting PARP1 mRNA stability.
Li H; Wang C; Lan L; Yan L; Li W; Evans I; Ruiz EJ; Su Q; Zhao G; Wu W; Zhang H; Zhou Z; Hu Z; Chen W; Oliveira JM; Behrens A; Reis RL; Zhang C
Cell Mol Life Sci; 2022 Feb; 79(3):135. PubMed ID: 35179655
[TBL] [Abstract][Full Text] [Related]
8. HOXA13 contributes to gastric carcinogenesis through DHRS2 interacting with MDM2 and confers 5-FU resistance by a p53-dependent pathway.
Han Y; Song C; Wang J; Tang H; Peng Z; Lu S
Mol Carcinog; 2018 Jun; 57(6):722-734. PubMed ID: 29436749
[TBL] [Abstract][Full Text] [Related]
9. Triptolide has anticancer and chemosensitization effects by down-regulating Akt activation through the MDM2/REST pathway in human breast cancer.
Xiong J; Su T; Qu Z; Yang Q; Wang Y; Li J; Zhou S
Oncotarget; 2016 Apr; 7(17):23933-46. PubMed ID: 27004407
[TBL] [Abstract][Full Text] [Related]
10. MDM2 is a useful prognostic biomarker for resectable gastric cancer.
Ye Y; Li X; Yang J; Miao S; Wang S; Chen Y; Xia X; Wu X; Zhang J; Zhou Y; He S; Tan Y; Qiang F; Li G; Røe OD; Zhou J
Cancer Sci; 2013 May; 104(5):590-8. PubMed ID: 23347235
[TBL] [Abstract][Full Text] [Related]
11. Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers.
Li X; Zhou S; Abrahams CL; Krimm S; Smith J; Bajjuri K; Stephenson HT; Henningsen R; Hanson J; Heibeck TH; Calarese D; Tran C; Yin G; Stafford RL; Yam AY; Kline T; De Almeida VI; Sato AK; Lupher M; Bedard K; Hallam TJ
Mol Cancer Ther; 2023 Feb; 22(2):155-167. PubMed ID: 36459691
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of nuclear-enriched abundant transcript 1 confers oxaliplatin resistance to gastric cancer.
Li Y; Peng C; Fang C; Huang K
Cell Biol Int; 2020 Feb; 44(2):446-455. PubMed ID: 31617275
[TBL] [Abstract][Full Text] [Related]
13. Peiminine serves as an adriamycin chemosensitizer in gastric cancer by modulating the EGFR/FAK pathway.
Tang Q; Wang Y; Ma L; Ding M; Li T; Nie Y; Gu Z
Oncol Rep; 2018 Mar; 39(3):1299-1305. PubMed ID: 29328433
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial ROS accumulation inhibiting JAK2/STAT3 pathway is a critical modulator of CYT997-induced autophagy and apoptosis in gastric cancer.
Cao Y; Wang J; Tian H; Fu GH
J Exp Clin Cancer Res; 2020 Jun; 39(1):119. PubMed ID: 32576206
[TBL] [Abstract][Full Text] [Related]
15. Oncostatin M receptor, positively regulated by SP1, promotes gastric cancer growth and metastasis upon treatment with Oncostatin M.
Yu Z; Li Z; Wang C; Pan T; Chang X; Wang X; Zhou Q; Wu X; Li J; Zhang J; Liu B; Zhu Z; Su L
Gastric Cancer; 2019 Sep; 22(5):955-966. PubMed ID: 30778797
[TBL] [Abstract][Full Text] [Related]
16. Activated HIF1α of tumor cells promotes chemoresistance development via recruiting GDF15-producing tumor-associated macrophages in gastric cancer.
Yu S; Li Q; Yu Y; Cui Y; Li W; Liu T; Liu F
Cancer Immunol Immunother; 2020 Oct; 69(10):1973-1987. PubMed ID: 32388677
[TBL] [Abstract][Full Text] [Related]
17. TEAD4 modulated LncRNA MNX1-AS1 contributes to gastric cancer progression partly through suppressing BTG2 and activating BCL2.
Shuai Y; Ma Z; Liu W; Yu T; Yan C; Jiang H; Tian S; Xu T; Shu Y
Mol Cancer; 2020 Jan; 19(1):6. PubMed ID: 31924214
[TBL] [Abstract][Full Text] [Related]
18. PIN1 Inhibition Sensitizes Chemotherapy in Gastric Cancer Cells by Targeting Stem Cell-like Traits and Multiple Biomarkers.
Zhang ZZ; Yu WX; Zheng M; Liao XH; Wang JC; Yang DY; Lu WX; Wang L; Zhang S; Liu HK; Zhou XZ; Lu KP
Mol Cancer Ther; 2020 Mar; 19(3):906-919. PubMed ID: 31879364
[TBL] [Abstract][Full Text] [Related]
19. Circular RNA circCCDC9 acts as a miR-6792-3p sponge to suppress the progression of gastric cancer through regulating CAV1 expression.
Luo Z; Rong Z; Zhang J; Zhu Z; Yu Z; Li T; Fu Z; Qiu Z; Huang C
Mol Cancer; 2020 May; 19(1):86. PubMed ID: 32386516
[TBL] [Abstract][Full Text] [Related]
20. miR-135a promotes gastric cancer progression and resistance to oxaliplatin.
Yan LH; Chen ZN; Li-Li ; Chen J; Wei WE; Mo XW; Qin YZ; Lin Y; Chen JS
Oncotarget; 2016 Oct; 7(43):70699-70714. PubMed ID: 27683111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
